Nicusor Iftimia | Precision Medicine | Innovative Research Award | 2701

Published on by Top Pharmaceutical

Innovative Research Award

Nicusor Iftimia
PSI, United States

Research Profile
Affiliation PSI
Country United States
Scopus ID 6603766089
Documents 177
Citations 4,524
h-index 36
Subject Area Precision Medicine
Event International Top Pharmaceutical Awards
ORCID 0000-0002-7713-6972

The Innovative Research Award recognizes researchers whose sustained scientific contributions have significantly advanced their respective disciplines through original research, technological innovation, and scholarly impact. Nicusor Iftimia has established a distinguished research profile in precision medicine and biomedical imaging, with extensive publications, a strong citation record, and interdisciplinary contributions that have influenced translational healthcare research.[1] His scholarly work spans optical imaging technologies, diagnostic instrumentation, and clinical applications that support improved patient outcomes.[2]

Abstract

Nicusor Iftimia has developed an internationally recognized research portfolio focused on precision medicine, biomedical optics, and advanced diagnostic technologies. His scientific investigations have supported improvements in optical coherence tomography, image-guided diagnostics, and translational biomedical engineering. The combination of a high publication output, extensive citations, and measurable scholarly influence demonstrates the sustained academic excellence expected for recognition through the Innovative Research Award.[1]

Keywords

Precision Medicine, Optical Coherence Tomography, Biomedical Imaging, Diagnostic Instrumentation, Biomedical Engineering, Clinical Imaging, Medical Devices, Translational Medicine, Optical Diagnostics, Innovative Research.

Introduction

Precision medicine continues to transform healthcare by integrating advanced imaging technologies with patient-specific diagnostic strategies. Researchers working at the intersection of engineering, optics, and medicine contribute substantially to this evolving field through innovations that improve disease detection and clinical decision-making. Nicusor Iftimia has consistently contributed to these developments through multidisciplinary research involving optical technologies and biomedical instrumentation.[2]

Research Profile

Nicusor Iftimia has established a distinguished research profile in precision medicine through extensive contributions to biomedical optics, optical coherence tomography, and advanced medical imaging technologies. His academic portfolio comprises 177 Scopus-indexed publications, more than 4,524 citations, and an h-index of 36, demonstrating sustained scholarly productivity and international research influence. His work emphasizes the development of innovative diagnostic methods and translational biomedical engineering solutions that bridge laboratory research with clinical practice. The breadth of his publications, collaborative research activities, and measurable scientific impact highlight his continued contributions to advancing precision medicine and healthcare technologies.[1][2]

Research Contributions

The research contributions of Nicusor Iftimia emphasize the integration of optical technologies with clinical practice. His publications have supported advances in non-invasive imaging, medical diagnostics, and translational biomedical engineering, enabling more accurate disease assessment and supporting innovation within precision healthcare systems.[3]

Publications

Nicusor Iftimia has authored 177 Scopus-indexed publications covering precision medicine, biomedical optics, optical coherence tomography, medical imaging, and diagnostic instrumentation. His scholarly work has been published in internationally recognized peer-reviewed journals and conference proceedings, demonstrating consistent research productivity and interdisciplinary collaboration. These publications have significantly contributed to the advancement of non-invasive imaging technologies, clinical diagnostics, and translational biomedical engineering. The sustained quality and impact of his research output are reflected by a strong citation record and continued recognition within the global scientific community.[1][2]

Research Impact

The citation metrics and publication record indicate sustained international recognition within biomedical engineering and medical imaging. The research has contributed to technological innovation, interdisciplinary collaboration, and scientific knowledge transfer across academic and healthcare communities.[1]

Award Suitability

Based on measurable scholarly indicators, interdisciplinary research contributions, and international scientific visibility, Nicusor Iftimia demonstrates characteristics consistent with the objectives of the International Top Pharmaceutical Awards. His sustained research productivity, technological innovation, and influence within precision medicine provide a strong academic foundation for consideration for the Innovative Research Award.[4]

Conclusion

Nicusor Iftimia’s academic profile reflects long-term excellence in biomedical optics, precision medicine, and diagnostic innovation. His publication history, citation impact, and interdisciplinary research achievements illustrate continued contributions to scientific advancement and demonstrate the qualities recognized through international research excellence awards.[1]

References

  1. Elsevier. (n.d.). Scopus author details: Nicusor Iftimia, Author ID 6603766089. Scopus. https://www.scopus.com/authid/detail.uri?authorId=6603766089
  2. Iftimia, N., Yadav, P., Primrose, M., Maguluri, G., Jones, J., Grimble, J., & Sheth, R. A. (2026). AI-Assisted OCT Imaging for Core Needle Biopsy Guidance: The 1st in Humans Study.Β https://doi.org/10.3390/diagnostics16050811
  3. Sampani, K., Mujat, M., Patel, A. H., Kang, C., Iftimia, N., Chatziralli, I., & Sun, J. K. (2024). Characterizing Vascular Wall and Lumen Caliber in Eyes with Diabetic Retinopathy Based on Adaptive Optics Scanning Laser Ophthalmoscopy.Β https://doi.org/10.3390/diagnostics14182020
  4. Steinberg, R., Meehan, J., Tavrow, D., Maguluri, G., Grimble, J., Primrose, M., & Iftimia, N. (2024). Assessing Lung Fibrosis with ML-Assisted Minimally Invasive OCT Imaging.https://doi.org/10.3390/diagnostics14121243
  5. Maguluri, G., Grimble, J., Mujat, M., Park, J., Caron, A., & Iftimia, N. (2022). Fiber-based hand-held RCM-OCT probe for noninvasive assessment of skin lesions and therapy guidance. https://doi.org/10.1002/tbio.202200002

Mihaela Minea | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Mihaela Minea β€” Ovidius University of ConstanΘ›a
Mihaela Minea
Affiliation Ovidius University of ConstanΘ›a
Country Romania
Scopus ID 58509570100
Documents 65
Citations 67
h-index 4
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Mihaela Minea is associated with Ovidius University of ConstanΘ›a, Romania, and has contributed to the interdisciplinary field of personalized medicine, rehabilitation sciences, and clinical evaluation methodologies. Her academic profile reflects scholarly engagement in rehabilitation assessment, gait analysis, and evidence-based healthcare approaches relevant to modern pharmaceutical and therapeutic research practices.[1] Her publication activity and citation profile demonstrate continuing participation in applied medical research with emphasis on patient-centered clinical outcomes and rehabilitation innovation.[2]

Abstract

This academic recognition article presents an overview of the scholarly profile and research contributions of Mihaela Minea in the domain of personalized medicine and rehabilitation sciences. Her work includes research on computerized gait analysis, rehabilitation outcomes, and clinical assessment methodologies. The research profile demonstrates involvement in interdisciplinary healthcare research integrating rehabilitation sciences with evidence-based medical evaluation frameworks. The publication record and citation activity indicate continuing academic participation in applied medical and pharmaceutical research relevant to patient-centered healthcare advancement.[1][3]

Keywords

Personalized Medicine, Rehabilitation Sciences, Clinical Research, Gait Analysis, Evidence-Based Medicine, Pharmaceutical Research, Osteoarthritis Rehabilitation, Healthcare Innovation, Medical Assessment, Research Evaluation

Introduction

Personalized medicine has become an important area within modern healthcare systems due to its focus on individualized therapeutic strategies, rehabilitation optimization, and patient-centered clinical interventions. Researchers working in this field contribute to the development of assessment methodologies that improve rehabilitation outcomes and evidence-based healthcare decision-making. Mihaela Minea has participated in research activities related to rehabilitation analysis and clinical outcome assessment, particularly within gait evaluation and osteoarthritis rehabilitation studies.[2] Such investigations support broader advancements in clinical rehabilitation sciences and therapeutic monitoring systems relevant to pharmaceutical and healthcare applications.[4]

Research Profile

The research profile of Mihaela Minea includes scholarly contributions indexed within Scopus author databases and related scientific platforms. Her documented academic activities involve publications associated with rehabilitation medicine, gait analysis technologies, and clinical healthcare evaluation systems.[1] The available citation metrics indicate an active contribution to interdisciplinary medical research with recognized engagement in healthcare-oriented investigations. The combination of publication records, citation activity, and subject specialization demonstrates sustained involvement in patient-focused rehabilitation studies and evidence-driven clinical methodologies.[5]

Research Contributions

The documented research contributions of Mihaela Minea include involvement in studies examining rehabilitation outcomes and computerized gait analysis systems for patients affected by knee osteoarthritis. These studies contribute to the understanding of rehabilitation effectiveness and objective clinical evaluation approaches in musculoskeletal healthcare management.[2] Research activities in rehabilitation sciences are increasingly relevant for modern healthcare systems because they support therapeutic optimization, monitoring strategies, and individualized rehabilitation planning. The integration of digital analysis tools into rehabilitation research also reflects broader trends in precision medicine and data-informed healthcare delivery.[6]

Publications

Selected scientific publications associated with Mihaela Minea demonstrate research interest in rehabilitation science, clinical assessment methodologies, and gait analysis applications in osteoarthritis rehabilitation.[2] These publications contribute to the broader scientific understanding of rehabilitation monitoring and healthcare evaluation systems relevant to personalized therapeutic approaches.[3]

Research Impact

Research impact within rehabilitation sciences is often evaluated through publication indexing, citation activity, and interdisciplinary relevance. The available citation record associated with Mihaela Minea indicates academic recognition within clinical and rehabilitation research communities.[1] Her scholarly work contributes to evidence-based rehabilitation practices and supports continuing discussions regarding digital clinical assessment technologies and patient-centered rehabilitation models. Such contributions are relevant to healthcare professionals, rehabilitation specialists, and medical researchers interested in outcome-oriented therapeutic evaluation systems.[4]

Award Suitability

Mihaela Minea demonstrates suitability for recognition through the Best Researcher Award based on her documented academic contributions, indexed research profile, and participation in rehabilitation and personalized medicine studies. Her scholarly activities align with the objectives of the International Top Pharmaceutical Awards, which recognize meaningful scientific engagement and interdisciplinary healthcare research contributions.[5] The combination of research activity, publication records, and citation visibility supports recognition within professional academic and clinical research environments. Her contributions further reflect continuing efforts toward evidence-based rehabilitation assessment and healthcare innovation.[6]

Conclusion

Mihaela Minea has contributed to the advancement of rehabilitation sciences and personalized medicine through scholarly participation in gait analysis and clinical rehabilitation research. Her academic profile reflects interdisciplinary engagement in evidence-based healthcare methodologies and rehabilitation assessment systems. The indexed research record, citation activity, and continuing relevance of her scientific work support recognition within professional medical and pharmaceutical research communities. These contributions remain relevant to contemporary discussions surrounding patient-centered healthcare, rehabilitation optimization, and digital clinical evaluation technologies.[1][3]

References

  1. Elsevier. (n.d.). Scopus author details: Mihaela Minea, Author ID 58509570100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58509570100
  2. Minea, M., et al. (2023). Using Computerised Gait Analysis to Assess Changes After Rehabilitation in Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Gait Speed Improvement. Healthcare.DOI: https://doi.org/10.3390/healthcare11050639

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Published on by Top Pharmaceutical

Jonathan Ejie | Personalized Medicine | Best Research Article Award

Mr. Jonathan Ejie, UCSF, United States

Mr. Jonathan Ejie is an aspiring physician-scientist currently pursuing his M.D. at UCSF 🩺 (Class of 2026), following a B.S. in Electrical Engineering & Computer Science from UC Berkeley πŸ’». His research spans oncology, radiology, and AI in healthcare, with published work in Cancers (2025) and upcoming studies in Nature Communications πŸ“Š. Jonathan integrates data science 🧠 with clinical insights, contributing to health equity, quality improvement, and surgical education. A mentor, tutor, and award-winning leader πŸ…, he co-founded the UCSF Futbol Club and serves underserved communities through advocacy and outreach.

Publication ProfileΒ 

Orcid

Education

Mr. Jonathan Ejie is an exceptional scholar whose educational journey bridges medicine and technology. He is currently pursuing his Doctor of Medicine (M.D.) degree at the prestigious University of California, San Francisco (UCSF) πŸ₯, with an expected graduation in 2026. Prior to this, he earned a Bachelor of Science in Electrical Engineering and Computer Science (EECS) πŸ’» from the University of California, Berkeley, graduating in 2022. His strong foundation in both engineering and clinical science equips him with a unique interdisciplinary perspective πŸ€–πŸ©Ί, positioning him at the forefront of innovation in digital health and precision medicine.

Experience

Mr. Jonathan Ejie brings a blend of academic support and compassionate service to his professional journey. As an MCAT Physics Tutor at UCSF (2023), he guided 15+ students through complex physics concepts πŸ“˜βš›οΈ. Earlier, at Contra Costa College (2019–2021), he tutored mathematics from Algebra to Calculus βž•πŸ“. His volunteer work includes providing first aid at athletic events πŸƒβ€β™‚οΈπŸ©Ή, teaching surgical skills to high school students at UCSF πŸ§΅πŸ§‘β€βš•οΈ, and serving as a Health Advocate at West County Health Center πŸ’¬πŸ©Ί, helping underserved patients access vital community resources. His dedication reflects a strong commitment to both education and public health.

Awards

Mr. Jonathan Ejie has been recognized for his academic excellence and impactful contributions to medicine and research. In 2024, he was honored with the prestigious Sinkler Miller Medical Association Scholarship πŸŽ–οΈ, sponsored by Gilead, celebrating his commitment to health equity and academic distinction. He also received the UCSF School of Medicine Summer Explore Fellowship Grant 🌟, supporting his innovative pursuits in medical research. In May 2023, Jonathan earned the Inquiry Conference Travel and Dissemination Award βœˆοΈπŸ“Š, which enabled him to share his scholarly findings on a larger stage. These accolades reflect his rising potential and leadership in healthcare.

Research FocusΒ 

Mr. Jonathan Ejie’s research focus lies at the intersection of oncology, health disparities, and medical data science. His standout work on the β€œOngoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer” πŸ“‰πŸ©Ί highlights critical inequities in healthcare delivery across race, geography, and insurance status. Combining his background in medicine πŸ§‘β€βš•οΈ and computer science πŸ’», Jonathan leverages data analysis and machine learning πŸ€–πŸ“Š to drive systemic improvements in cancer care. His work reflects a commitment to equity, evidence-based medicine, and the pursuit of personalized, accessible treatment strategies for vulnerable cancer populations.

Publication Top Notes

  • Ongoing Failure to Deliver Guideline-Concordant Care for Patients with Pancreatic Cancer

Mario Romeo | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Mario Romeo | Precision Medicine | Best Researcher Award

Dr. Mario Romeo, Dipartimento di Medicina di Precisione, UniversitΓ  degli Studi della Campania, LuigiVanvitelli, Italy

Dr. Mario Romeo is an accomplished medical doctor and researcher specializing in Digestive System Diseases. Graduating with top honors in Medicine and Surgery from the University of Campania β€œLuigi Vanvitelli” πŸŽ“, he also earned a specialization in Gastroenterology and is pursuing a Ph.D. in Clinical and Experimental Medical Sciences. His research spans gut microbiota 🧫, liver disease πŸ₯, and metabolic dysfunction. A recipient of over 20 international awards πŸ†, Dr. Romeo is widely recognized for his groundbreaking work in hepatology and gastroenterology. He actively contributes to scientific societies and fosters innovation in digestive health care.

Publication ProfileΒ 

Orcid

Education

Dr. Mario Romeo πŸŽ“ began his academic journey with honors, earning his Diploma di MaturitΓ  Classica from Liceo Classico Gneo Nevio in June 2014 with a perfect score of 100/100 con lode πŸ“œ. He continued his excellence at the University of Campania β€œLuigi Vanvitelli,” completing his Laurea in Medicina e Chirurgia in July 2020 with 110/110 con lode 🩺, presenting a thesis on sarcopenia in compensated liver cirrhosis. He further specialized in Digestive System Diseases, earning his diploma in January 2025 with 50/50 con lode 🌟. His thesis explored RPR as a non-invasive tool in liver disease prediction.

Awards

Dr. Mario Romeo πŸ… has received numerous prestigious scholarships and awards in recognition of his excellence in hepatology and gastroenterology. Highlights include competitive fellowships like the AISF MasterClass 2022 πŸŽ“ and UEG Clinical Visiting Fellowship 2025 🌍. He has earned multiple travel grants ✈️ and best presentation prizes πŸ† at top events such as UEG Week, FISMAD, EASL, and ESCI for groundbreaking research on liver diseases, MAFLD, gut microbiota, and non-invasive biomarkers. His multidisciplinary β€œCoCoNut” protocol 🍏 also gained international acclaim. These accolades affirm his dynamic role in advancing liver research and patient care through innovation and collaboration.

Research FocusΒ 

Dr. Mario Romeo’s research focus lies predominantly in Hepatology and Gastroenterology, with a strong emphasis on Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), liver cirrhosis, and gut-liver axis dynamics 🧬🍽️. His work explores non-invasive biomarkers, body composition, oxidative stress, and gut microbiota 🧫, highlighting their roles in disease progression and clinical outcomes. He also investigates multidisciplinary management strategies combining nutritional, psychological, and pharmacological interventions πŸ₯—πŸ§ πŸ’Š. Dr. Romeo contributes significantly to understanding liver-related complications like sarcopenia, dysgeusia, and hepatocellular carcinoma 🎯. His innovative, patient-centered research enhances predictive diagnostics and therapeutic approaches in chronic liver diseases.

Publication Top Notes

  • Spleen Area Affects the Performance of the Platelet Count–Based Non-invasive Tools in Predicting First Hepatic Decompensation in Metabolic Dysfunction–Associated Steatotic Liver Disease Cirrhosis
  • Nutritional and Psychological Support as a Multidisciplinary Coordinated Approach in the Management of Chronic Liver Disease: A Scoping Review
  • Letter: Different Risk of Acute Variceal Bleeding According to the Liver Disease Aetiology in Decompensated Cirrhosis Patients Receiving Carvedilol‐Based Primary Prophylaxisβ€”May Insulin Resistance Unloose This Gordian Knot?
  • Exploring the Classic and Novel Pathogenetic Insights of Plastic Exposure in the Genesis and Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • The Role of the Gut–Biliary–Liver Axis in Primary Hepatobiliary Liver Cancers: From Molecular Insights to Clinical Applications
  • Primary biliary cholangitis, Celiac Disease, and MASLD: the triumvirate of steatosis. How should we manage this triple overlap?
  • Clinical Applications of Artificial Intelligence (AI) in Human Cancer: Is It Time to Update the Diagnostic and Predictive Models in Managing Hepatocellular Carcinoma (HCC)?
  • FLAME: Training and Validating a Newly Conceived Model Incorporating Alpha-Glutathione-S-Transferase Serum Levels for Predicting Advanced Hepatic Fibrosis and Acute Cardiovascular Events in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
  • Dysgeusia in MASLD-related advanced chronic liver disease (ACLD): a silent driver towards the β€œBermuda” triangle of malnutrition-sarcopenia-frailty severely affecting prognosis
  • Vanek’s Tumour as a Rare Cause of Dyspeptic Syndrome in a Patient with Primary Biliary Cholangitis: A Case Report
  • Systemic Oxidative Stress Correlates with Sarcopenia and Pruritus Severity in Primary Biliary Cholangitis (PBC): Two Independent Relationships Simultaneously Impacting the Quality of Lifeβ€”Is the Low Absorption of Cholestasis-Promoted Vitamin D a Puzzle Piece?
  • Prediction of Clinical Trajectory in HCV-Related ACLD after SVR: Role of Liver Stiffness in a 5-Years Prospective Study

Jian Shi | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Jian Shi | Precision Medicine | Best Researcher Award

Assoc. Prof. Dr. Jian Shi, Neurology of UCSF, United States

Assoc. Prof. Dr. Jian Shi is a distinguished neuroscientist at the University of California, San Francisco, with a Ph.D. in Neurobiology from Navy Medical University, China. 🧬 He completed postdoctoral training at the University of Texas Southwestern Medical Center, focusing on neuroscience. His research integrates brain injury, neurodegenerative diseases, and glioblastoma with cutting-edge AI and bioinformatics tools. πŸ§ͺ🧠 Dr. Shi has authored highly cited publications and received numerous accolades, including the APS Outstanding Paper Award. 🌟 A dedicated mentor and educator, he actively contributes to diversity and public service in neurology and biomedical research.

Publication Profile

Google Scholar

Education

Assoc. Prof. Dr. Jian Shi began his academic journey at the National University of Defense Technology in Hunan Province, China, earning both his B.S. and M.S. degrees in Biomechanics. βš™οΈπŸ“˜ He then pursued his Ph.D. in Neurobiology under the mentorship of Dr. Lu Changlin at the prestigious Navy Medical University in Shanghai. 🧬πŸ₯ Driven by a passion for neuroscience, he completed his postdoctoral training at the University of Texas Southwestern Medical Center under the guidance of Dr. Steven G. Kernie, focusing on advanced neuroscience research. πŸ§ πŸ”¬ His academic foundation bridges biomechanics and cutting-edge neurobiological science.

Awards

Assoc. Prof. Dr. Jian Shi has received numerous accolades recognizing his excellence in research and education. πŸ‡¨πŸ‡³ He was honored with the prestigious National Award for Scientific Progress, Level 2 in China πŸ₯‡πŸ”¬ and received the Award for Outstanding Scientists from Navy Medical University, where he also earned the Best Teacher Award for his commitment to academic excellence πŸ‘¨β€πŸ«πŸŒŸ. His groundbreaking work earned him the β€œTop 50 Most Cited Article Award” from the Journal of Clinical Medicine πŸ“–πŸ“ˆ and the APS Outstanding Paper Award from Acta Pharmacologica Sinica πŸ§ͺπŸ…. He is also recognized as a Trusted Reviewer by the International Journal of Molecular Sciences πŸ§ βœ….

Research Focus

Assoc. Prof. Dr. Jian Shi’s research centers around neurobiology, with a strong emphasis on traumatic brain injury (TBI) 🧠πŸ’₯, neurodegeneration 🧬, neurogenesis 🌱, and molecular neuroscience. His work explores small molecule therapies, microglial activation, intranasal drug delivery πŸ’Š, and microRNA biomarkers, particularly in the context of glioblastoma and stroke. He also investigates brain repair mechanisms, exosomal signaling πŸ“¦, and neurotrophin-mimetic compounds. In recent years, his interdisciplinary work has extended to climate impact models 🌍 and machine learning applications πŸ€– in brain science, reflecting a comprehensive and innovative research portfolio in translational neuroscience and brain health.

Publication Top Notes

Small molecule BDNF mimetics activate TrkB signaling and prevent neuronal degeneration in rodents

Microglial activation induced by brain trauma is suppressed by post-injury treatment with a PARP inhibitor

Intranasal administration with NAD+ profoundly decreases brain injury in a rat model of transient focal ischemia

Considering exosomal miR-21 as a biomarker for cancer

The basic helix-loop-helix transcription factor olig2 is critical for reactive astrocyte proliferation after cortical injury

A small molecule p75NTRΒ ligand protects neurogenesis after traumatic brain injury

MicroRNAs as biomarkers for human glioblastoma: progress and potential

Regulatory networks between neurotrophins and miRNAs in brain diseases and cancers

Triggering receptor expressed on myeloid cells-2 expression in the brain is required for maximal phagocytic activity and improved neurological outcomes following experimental …

Beneficial effects of minocycline and botulinum toxin–induced constraint physical therapy following experimental traumatic brain injury

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna Γ¨ un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’UniversitΓ  di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni πŸ“š. La sua missione Γ¨ migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. πŸ§ͺ This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

πŸ”¬ Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. πŸš€ In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the β€œPancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. πŸ‡«πŸ‡· In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding β€˜Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor β€˜AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction

Mario Leporace | Personalized Medicine | Best Innovation Award

Published on by Top Pharmaceutical

Mario Leporace | Personalized Medicine | Best Innovation Award

Prof. Dr. Mario Leporace, Hospital and University, Italy

Prof. Dr. Mario Leporace is a distinguished Clinical Radiologist at the Department of Nuclear Medicine and Theragnostics, β€œMariano Santo” Hospital, Cosenza, Italy. With expertise in oncologic imaging, hybrid and molecular imaging, and cardiovascular radiology, he is renowned for his advanced diagnostic work using X-ray, CT, MRI, PET/CT, and SPECT/CT. He holds a Master’s in Interventional Oncology and has contributed to over 15 peer-reviewed publications. His professional journey spans top institutions in Rome and Cosenza, marking a career dedicated to innovation in radiology and nuclear medicine.

Publication Profile

Scopus

Education

Prof. Dr. Mario Leporace πŸŽ“ is a distinguished expert in interventional oncology and radiology. In 2022, he earned a Master’s Degree in Interventional Oncology from Fondazione Policlinico Universitario A. Gemelli IRCCS in Rome, with a thesis on thermal ablation of bone metastases πŸ”₯🦴. From 2001 to 2005, he completed his post-graduate certification in Radiology at the University of Rome β€œTor Vergata” πŸ₯, graduating cum laude with a thesis on hybrid imaging πŸ§ πŸ“Έ. He also obtained his Degree in Medicine and Surgery from the same university (1995–2001), graduating with top honors and a thesis in vascular imaging πŸ«€πŸ§¬.

Experience

Prof. Dr. Mario Leporace 🩺 has an extensive career in radiology and nuclear medicine, showcasing over two decades of dedicated medical service. Since October 2017, he has been serving in the Department of Nuclear Medicine and Theragnostics at β€œMariano Santo” Hospital in Cosenza, Italy βš›οΈπŸ₯. From May 2016 to September 2017, he worked at the Department of Radiology, β€œAnnunziata” Hospital 🏨. Earlier, from March 2006 to April 2016, he contributed to the European Hospital in Rome, and concurrently, from November 2005 to April 2016, served at the Aurelia Hospital in Rome πŸ›οΈπŸ”¬, strengthening his clinical expertise across institutions.

Research Focus

Prof. Dr. Mario Leporace focuses his research on Thermal Ablation with Magnetic Resonance-guided Focused Ultrasound Surgery (MRgFUS) πŸ”¬πŸ§ . His work bridges medical physics and oncological applications, exploring non-invasive treatments that use focused ultrasound energy to thermally ablate tumors with MRI precision guidance 🎯. This technique offers cutting-edge therapeutic possibilities in fields such as oncology, neurology, and women’s health πŸ§¬πŸ’‘. Prof. Leporace’s contributions advance both the clinical outcomes and technological innovation of MRgFUS, making him a key figure in image-guided therapy, minimally invasive surgery, and cancer treatment research .

Publication Top Notes

The Thermal Ablation with MRgFUS: From Physics to Oncological Applications

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Nigatu Gebrehiwot | Precision Medicine | Best Researcher Award

Dr. Nigatu Gebrehiwot, Zhengzhou University, China

Dr. Nigatu Gebrehiwot is a dedicated PhD candidate in Pharmacology at Zhengzhou University, China, specializing in drug safety evaluation. He holds a Master’s in Clinical and Administrative Pharmacy from Xi’an Jiaotong University and a Bachelor of Pharmacy from Mekelle University, where he was recognized as an outstanding student. A published researcher and global presenter, Dr. Gebrehiwot has earned accolades including recognition at ISPOR in Barcelona. He is actively involved in multiple international scientific societies and brings strong expertise in pharmacotherapy, academic writing, and collaborative healthcare research. His work explores methionine metabolism and innovative therapeutic strategies.

Publication Profile

Orcid

Education

Dr. Nigatu Gebrehiwot holds a Master’s degree in Clinical and Administrative Pharmacy from Xi’an Jiaotong University, where his research earned an award at the 21st European Congress ISPOR Health Outcome Research Conference in Barcelona, Spain. πŸ… He also earned a Bachelor’s degree in Pharmacy from Mekelle University, where he was recognized as the most outstanding student in his class. πŸŽ“ His academic achievements reflect his dedication to advancing the field of pharmacy, blending clinical expertise with research excellence. Dr. Gebrehiwot’s work continues to impact the healthcare landscape positively.

Experience

Dr. Nigatu Gebrehiwot is currently a Ph.D. candidate in Pharmacology at the Center for Drug Safety Evaluation and Research, Zhengzhou University, Henan, China, since September 2022. πŸŽ“ Prior to this, he served as the Principal Scientific Officer at the Federal Ministry of Health (FMOH) in Ethiopia from June 2020 to 2021. During his tenure, Dr. Gebrehiwot managed national disease programs and medicines, overseeing the funding and evaluation of treatment guidelines and drug therapy protocols in accordance with Ethiopian legislation and EFDA guidelines. πŸ’Š He also led technical committees focused on antimicrobial therapy, cancer, and chronic disease management.

Awards

Dr. Nigatu Gebrehiwot received a prestigious award for his research abstract at the 21st European Congress ISPOR Health Outcome Research conference in Barcelona, Spain. πŸ† This recognition underscores the significant impact of his work in the field of pharmacology and health outcome research. 🌍 His contributions continue to advance knowledge and influence healthcare practices, making him a respected figure in his field. πŸ’‘ Dr. Gebrehiwot’s dedication to research excellence and his ability to address critical health issues have earned him well-deserved acknowledgment on an international stage.

Research Focus

Dr. Nigatu Tadesse’s research primarily focuses on molecular alterations in disease processes, with an emphasis on metabolic pathways and their potential as diagnostic and therapeutic targets. His work on gastric intestinal metaplasia and methionine metabolism sheds light on novel approaches to diagnosis and treatment. Additionally, Dr. Tadesse has contributed significantly to pharmacology, particularly the study of traditional medicines like Dioscorea zingiberensis, investigating its phytochemistry, clinical applications, and toxicity. His research also extends to industrial processes, such as wastewater treatment in diosgenin production. His interdisciplinary work connects biomedicine, pharmacology, and environmental science.

Publication Top Notes

Molecular Alterations in Gastric Intestinal Metaplasia Shed Light on Alteration of Methionine Metabolism: Insight into New Diagnostic and Treatment Approaches

Knowledge, attitude and antibiotic prescribing patterns of medical doctors providing free healthcare in the outpatient departments of public hospitals in Sierra Leone: A national cross-sectional study

Dioscorea zingiberensis C. H. Wright: An overview on its traditional use, phytochemistry, pharmacology, clinical applications, quality control, and toxicity

First total synthesis of a novel amide alkaloid derived from Aconitum taipeicum and its anticancer activity

Methods to treat the industrial wastewater in diosgenin enterprises produced from Diosorea zingiberensis C. H. Wright

Safety investigation on total steroid saponins extracts from Dioscorea zingiberensis C.H. Wright: Sub-acute and chronic toxicity studies on dogs

Hui Huang | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Hui Huang | Precision Medicine | Best Researcher Award

Prof. Dr. Hui Huang, The Eighth Affiliated Hospital of Sun Yat-Sen University, China

Prof. Hui Huang is Vice President of The Eighth Affiliated Hospital of Sun Yat-sen University and a renowned expert in vascular calcification and chronic disease prevention. πŸ“š He has authored 100+ high-impact papers in journals like Circulation and J Clin Invest, earning honors like ESI Highly Cited and Top 100 High-Value Papers. πŸ† A recipient of China’s Excellent Young Scientists Fund, he directs multiple prestigious laboratories and holds several international patents. πŸ”¬ His research explores metabolic and immune mechanisms in chronic kidney disease and vascular aging.

Publication Profile

Scopus

Education

Prof. Dr. Hui Huang has authored over 100 peer-reviewed papers in prestigious journals such as Circulation (2022, 2023), J Clin Invest. (2021, 2022, 2025), Hypertension (2018, 2021, 2022), STTT (2022–2024), Kidney Int. (2024), and Cardiovasc Res. (2023) πŸ“š. His impactful work has earned distinctions like ESI Highly Cited Papers, Top 100 High-Value Papers, and journal Cover Stories πŸ…. A recipient of China’s National Science Fund for Excellent Young Scholars πŸŽ“, he also led the development of the Expert Consensus on Vascular Calcification, offering vital clinical guidance for practitioners in the field of cardiovascular and renal medicine ❀️🩺.

Experience

Prof. Dr. Hui Huang has led more than 13 major research projects, predominantly funded by the National Natural Science Foundation of China (NSFC) πŸ”¬πŸ‡¨πŸ‡³. His groundbreaking work focuses on unraveling the innovative mechanisms behind arterial calcification, chronic kidney disease, and inflammation πŸ§ πŸ«€. These projects are long-term, high-budget, and scientifically robust, highlighting their critical importance on both national and global stages πŸŒπŸ’°. Through his pioneering research, Prof. Huang is driving transformative advancements in cardiovascular and renal health, contributing significantly to medical science and improving patient outcomes πŸš€πŸ©Ί.

Research Focus

Prof. Dr. Hui Huang is a leading researcher in biomedical sciences, with a strong focus on cardiovascular disease, immunology, toxicology, and metabolic disorders. Her work spans areas such as inflammation in the central nervous system, myocardial infarction, diabetes-related metabolomics, and environmental health risks like metal toxicity. πŸŒ‘οΈπŸ§ πŸ«€ She also explores digital therapeutics and sex-based differences in disease outcomes, making her contributions highly interdisciplinary. πŸ“ŠπŸ’» Her research integrates clinical, molecular, and environmental insights to develop novel strategies for disease prevention and treatment. A strong advocate for translational medicine, Prof. Huang bridges lab science with real-world health challenges.

Publication Top Notes

The Innate Immune Sensor Zbp1 Mediates Central Nervous System Inflammation Induced by Angiostrongylus Cantonensis by Promoting Macrophage Inflammatory Phenotypes

Targeted LC-MS/MS method of oxylipin profiling reveals differentially expressed serum metabolites in type 2 diabetes mice with panaxynol

Ellagic acid-enhanced biocompatibility and bioactivity in multilayer core-shell gold nanoparticles for ameliorating myocardial infarction injury

Sex difference in human diseases: mechanistic insights and clinical implications

Effect of plateletcrit and methylenetetrahydrofolate reductase (MTHFR) C677T genotypes on folic acid efficacy in stroke prevention

Digital therapeutics in hypertension: How to make sustainable lifestyle changes

Associations of essential metals with the risk of aortic arch calcification: a cross-sectional study in a mid-aged and older population of Shenzhen, China

Edwin Posadas | Precision Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Edwin Posadas | Precision Medicine | Best Researcher Award

Dr. Edwin Posadas, Cedars-Sinai Cancer, United States

Dr. Edwin M. Posadas is a distinguished oncologist and urologist specializing in prostate cancer research and treatment. He is a Professor at Cedars-Sinai Medical Center and UCLA, co-Director of the Cancer Therapeutics Program, and Medical Director of the Urologic Oncology Program. A Johns Hopkins graduate, he trained at the NIH and University of Michigan. Dr. Posadas has earned numerous accolades, including Castle Connolly Top Doctor and Sigma Xi Honors. An active researcher, mentor, and leader in oncology, he contributes to multiple scientific committees and journals, shaping the future of cancer care. πŸ“šπŸ”¬βœ¨

Publication Profile

orcid

Education

Dr. Edwin Posadas πŸŽ“ began his academic journey at Johns Hopkins University, earning dual B.E.S. degrees in Biomedical and Chemical Engineering (1993) with summa cum laude honors. His studies focused on biological transport systems and physiological fluid mechanics. He then pursued his M.D. at Johns Hopkins School of Medicine (1998) 🩺, followed by an internship and residency at the University of Michigan Medical Center (2001) πŸ₯. Further specializing, he completed a fellowship in Medical Oncology and Hematology (2005) 🧬 at the National Cancer Institute & National Heart, Lung, and Blood Institute, solidifying his expertise in cancer research and treatment. πŸ”¬πŸ’™

Professional Associations

Dr. Edwin Posadas 🩺 is an esteemed member of numerous professional associations and scholarly societies, reflecting his dedication to oncology, urology, and medical ethics. He joined the American Medical Association (1993) πŸ₯, Association of Philippine Physicians of America (1998) πŸ‡΅πŸ‡­, and American College of Physicians (1998) 🩻, later becoming a Fellow (2010) πŸŽ–οΈ. His contributions extend to the American Society of Clinical Oncology (2001) 🧬, American Association for Cancer Research (2001) πŸ”¬, and European Society of Medical Oncology (2012) 🌍. He also actively participates in cancer research initiatives, including the Cancer Moonshot Program (2016) πŸš€ and the Medical Oncology Association of Southern California (2022) 🌿.

Achievements

Dr. Edwin Posadas 🩺 has built a distinguished career in internal medicine and medical oncology, dedicated to advancing patient care and cancer research. In 2001, he became certified in Internal Medicine πŸ₯, laying the foundation for his expertise in diagnosing and managing complex diseases. His passion for oncology led him to further specialize, earning his Medical Oncology certification in 2019 πŸ§¬πŸŽ—οΈ. With decades of experience, he remains committed to innovative cancer treatments, translational research, and personalized patient care, making significant contributions to the oncology community through clinical practice, research, and professional collaborations. πŸ”¬πŸ’™

Research Focus

Dr. Edwin M. Posadas is a distinguished researcher specializing in prostate cancer πŸ”¬, metastasis 🧬, and nanotechnology-based diagnostics πŸ₯. His work focuses on understanding the molecular determinants of metastasis in prostate cancer, particularly liver and visceral metastases. He has contributed to the development of nanotechnology solutions for early cancer detection 🩸 and circulating tumor cell profiling. His research also explores the role of FYN kinase in cancer growth and motility. With multiple grants from the National Cancer Institute and Congressionally Directed Medical Research Programs, his pioneering work is advancing precision oncology and metastasis prevention in prostate cancer patients. πŸŽ—οΈ

Publication Top Notes

Determinants of Liver Metastasis

A Nanotechnology Solution for Early Detection of Micrometastatic Prostate Cancer After Radical Prostatectomy

A blood test to identify prostate cancer patients at risk for visceral metastasis

Thermoresponsive NanoVelcro CTC Purification System for Prostate Cancer Profiling

FYN Is a Key Regulator of Metastasis in Prostate Cancer

Targeting FYN in Prostate Cancer: A Key Regulator of Growth and Motility